Patents by Inventor Cristopher Van Hout

Cristopher Van Hout has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treatment Of Decreased Bone Mineral Density With Zinc And Ring Finger 3 (ZNRF3) Inhibitors
    Publication number: 20240076674
    Abstract: The present disclosure provides methods of treating patients having decreased bone mineral density, methods of identifying subjects having increased risk of developing decreased bone mineral density, methods of detecting human Zinc And Ring Finger 3 (ZNRF3) variant nucleic acid molecules and variant polypeptides, and ZNRF3 variant nucleic acid molecules and variant polypeptides.
    Type: Application
    Filed: June 14, 2023
    Publication date: March 7, 2024
    Inventors: Da-Wei Gong, Nehal Gosalia, Alan Shuldiner, Cristopher Van Hout, James Perry
  • Treatment Of Increased Lipid Levels With Sterol Regulatory Element Binding Transcription Factor 1 (SREBF1) Inhibitors
    Publication number: 20230263821
    Abstract: The present disclosure provides methods of treating subjects having increased lipid levels, methods of identifying subjects having an increased risk of developing an increased lipid level, methods of detecting human Sterol Regulatory Element Binding Transcription Factor 1 (SREBF1) variant nucleic acid molecules and variant polypeptides, and SREBF1 variant nucleic acid molecules and variant polypeptides.
    Type: Application
    Filed: October 17, 2022
    Publication date: August 24, 2023
    Inventors: Alan Shuldiner, Nehal Gosalia, Cristopher Van Hout, Da-Wei Gong, James A. Perry
  • Treatment of decreased bone mineral density with zinc and ring finger 3 (ZNRF3) inhibitors
    Patent number: 11713461
    Abstract: The present disclosure provides methods of treating patients having decreased bone mineral density, methods of identifying subjects having increased risk of developing decreased bone mineral density, methods of detecting human Zinc And Ring Finger 3 (ZNRF3) variant nucleic acid molecules and variant polypeptides, and ZNRF3 variant nucleic acid molecules and variant polypeptides.
    Type: Grant
    Filed: June 22, 2020
    Date of Patent: August 1, 2023
    Assignees: Regeneran Pharmaceuticals, Inc., University of Maryland, Baltimore
    Inventors: Da-Wei Gong, Nehal Gosalia, Alan Shuldiner, Cristopher Van Hout, James Perry
  • Treatment of increased lipid levels with sterol regulatory element binding transcription factor 1 (SREBF1) inhibitors
    Patent number: 11504390
    Abstract: The present disclosure provides methods of treating subjects having increased lipid levels, methods of identifying subjects having an increased risk of developing an increased lipid level, methods of detecting human Sterol Regulatory Element Binding Transcription Factor 1 (SREBF1) variant nucleic acid molecules and variant polypeptides, and SREBF1 variant nucleic acid molecules and variant polypeptides.
    Type: Grant
    Filed: March 19, 2020
    Date of Patent: November 22, 2022
    Assignees: Regeneron Pharmaceuticals, Inc., University of Maryland, Baltimore
    Inventors: Alan Shuldiner, Nehal Gosalia, Cristopher Van Hout, Da-Wei Gong, James A. Perry
  • Treatment Of Increased Lipid Levels With Sterol Regulatory Element Binding Protein Cleavage-Activating Protein (SCAP) Inhibitors
    Publication number: 20220323483
    Abstract: The present disclosure provides methods of treating subjects having increased lipid levels and/or increased triglyceride levels, methods of identifying subjects having an increased risk of developing an increased lipid level and/or increased triglyceride level, methods of detecting human Sterol Regulatory Element Binding Protein Cleavage-Activating Protein (SCAP) variant nucleic acid molecules and variant polypeptides, and SCAP variant nucleic acid molecules and variant polypeptides.
    Type: Application
    Filed: April 13, 2022
    Publication date: October 13, 2022
    Inventors: Da-Wei Gong, James A. Perry, Alan Shuldiner, Nehal Gosalia, Cristopher Van Hout
  • Rodent Model Of Increased Bone Mineral Density
    Publication number: 20220217956
    Abstract: The present disclosure provides rodent models of increased bone mineral density and/or bone mineral content, genetically modified rodents and isolated rodent cells or tissues having a disruption of one or both alleles of the Zinc and Ring Finger 3 (Znrf3) gene, knockout rodent Znrf3 DNA constructs, methods of producing genetically modified rodents, methods of producing Znrf3 knockout rodents, and methods of determining the effect of an agent for treating low bone mineral density and/or bone mineral content.
    Type: Application
    Filed: March 30, 2022
    Publication date: July 14, 2022
    Inventors: Yajun Tang, Alan Shuldiner, Cristopher Van Hout
  • Treatment of increased lipid levels with sterol regulatory element binding protein cleavage-activating protein (SCAP) inhibitors
    Patent number: 11331332
    Abstract: The present disclosure provides methods of treating subjects having increased lipid levels and/or increased triglyceride levels, methods of identifying subjects having an increased risk of developing an increased lipid level and/or increased triglyceride level, methods of detecting human Sterol Regulatory Element Binding Protein Cleavage-Activating Protein (SCAP) variant nucleic acid molecules and variant polypeptides, and SCAP variant nucleic acid molecules and variant polypeptides.
    Type: Grant
    Filed: March 19, 2020
    Date of Patent: May 17, 2022
    Assignees: Regeneron Pharmaceuticals, Inc., University of Maryland, Baltimore
    Inventors: Da-Wei Gong, James A. Perry, Alan Shuldiner, Nehal Gosalia, Cristopher Van Hout
  • Treatment Of Decreased Bone Mineral Density With Zinc And Ring Finger 3 (ZNRF3) Inhibitors
    Publication number: 20210002647
    Abstract: The present disclosure provides methods of treating patients having decreased bone mineral density, methods of identifying subjects having increased risk of developing decreased bone mineral density, methods of detecting human Zinc And Ring Finger 3 (ZNRF3) variant nucleic acid molecules and variant polypeptides, and ZNRF3 variant nucleic acid molecules and variant polypeptides.
    Type: Application
    Filed: June 22, 2020
    Publication date: January 7, 2021
    Inventors: Da-Wei Gong, Nehal Gosalia, Alan Shuldiner, Cristopher Van Hout, James Perry
  • B4GALT1 Variants And Uses Thereof
    Publication number: 20200399617
    Abstract: Variant B4GALT1 genomic, mRNA, and cDNA nucleic acid molecules, and polypeptides, methods of detecting the presence of these molecules, methods of modulating endogenous B4GALT1 genomic, mRNA, and cDNA nucleic acid molecules, and polypeptides, methods of ascertaining the risk of developing cardiovascular conditions by detecting the presence or absence of the variant B4GALT1 genomic, mRNA, and cDNA nucleic acid molecules, and polypeptides, and methods of treating cardiovascular conditions are provided herein.
    Type: Application
    Filed: July 2, 2020
    Publication date: December 24, 2020
    Inventors: May Montasser, Cristopher Van Hout, Alan Shuldiner, Giusy Della Gatta, Matthew Healy, Marja Puurunen
  • Treatment Of Increased Lipid Levels With Sterol Regulatory Element Binding Protein Cleavage-Activating Protein (SCAP) Inhibitors
    Publication number: 20200297753
    Abstract: The present disclosure provides methods of treating subjects having increased lipid levels and/or increased triglyceride levels, methods of identifying subjects having an increased risk of developing an increased lipid level and/or increased triglyceride level, methods of detecting human Sterol Regulatory Element Binding Protein Cleavage-Activating Protein (SCAP) variant nucleic acid molecules and variant polypeptides, and SCAP variant nucleic acid molecules and variant polypeptides.
    Type: Application
    Filed: March 19, 2020
    Publication date: September 24, 2020
    Inventors: Da-Wei Gong, James A. Perry, Alan Shuldiner, Nehal Gosalia, Cristopher Van Hout
  • Treatment Of Hyperglycemia With Solute Carrier Family 39 Member 5 (SLC39A5) Inhibitors
    Publication number: 20200297751
    Abstract: The present disclosure provides methods of treating subjects having increased serum glucose level and/or hyperglycemia, methods of identifying subjects having an increased risk of developing increased serum glucose level and/or hyperglycemia, and methods of detecting human Solute Carrier Family 39 Member 5 variant nucleic acid molecules and variant polypeptides.
    Type: Application
    Filed: March 12, 2020
    Publication date: September 24, 2020
    Inventors: Harikiran Nistala, Cristopher Van Hout, Lyndon Mitnaul, Anthony Marcketta
  • Treatment Of Increased Lipid Levels With Sterol Regulatory Element Binding Transcription Factor 1 (SREBF1) Inhibitors
    Publication number: 20200297752
    Abstract: The present disclosure provides methods of treating subjects having increased lipid levels, methods of identifying subjects having an increased risk of developing an increased lipid level, methods of detecting human Sterol Regulatory Element Binding Transcription Factor 1 (SREBF1) variant nucleic acid molecules and variant polypeptides, and SREBF1 variant nucleic acid molecules and variant polypeptides.
    Type: Application
    Filed: March 19, 2020
    Publication date: September 24, 2020
    Inventors: Alan Shuldiner, Nehal Gosalia, Cristopher Van Hout, Da-Wei Gong, James A. Perry
  • B4GALT1 cDNA variants and compositions comprising the same
    Patent number: 10738284
    Abstract: Variant B4GALT1 genomic, mRNA, and cDNA nucleic acid molecules, and polypeptides, methods of detecting the presence of these molecules, methods of modulating endogenous B4GALT1 genomic, mRNA, and cDNA nucleic acid molecules, and polypeptides, methods of ascertaining the risk of developing cardiovascular conditions by detecting the presence or absence of the variant B4GALT1 genomic, mRNA, and cDNA nucleic acid molecules, and polypeptides, and methods of treating cardiovascular conditions are provided herein.
    Type: Grant
    Filed: June 4, 2018
    Date of Patent: August 11, 2020
    Assignees: Regeneron Pharmaceuticals, Inc., University of Maryland, Baltimore
    Inventors: May Montasser, Cristopher Van Hout, Alan Shuldiner, Giusy Della Gatta, Matthew Healy, Marja Puurunen
  • B4GALT1 Variants And Uses Thereof
    Publication number: 20180346888
    Abstract: Variant B4GALT1 genomic, mRNA, and cDNA nucleic acid molecules, and polypeptides, methods of detecting the presence of these molecules, methods of modulating endogenous B4GALT1 genomic, mRNA, and cDNA nucleic acid molecules, and polypeptides, methods of ascertaining the risk of developing cardiovascular conditions by detecting the presence or absence of the variant B4GALT1 genomic, mRNA, and cDNA nucleic acid molecules, and polypeptides, and methods of treating cardiovascular conditions are provided herein.
    Type: Application
    Filed: June 4, 2018
    Publication date: December 6, 2018
    Inventors: May Montasser, Cristopher Van Hout, Alan Shuldiner, Giusy Della Gatta, Matthew Healy, Marja Puurunen